Welcome to HitGen


Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 28 February 2017
    HitGen and CRUK Enter Into Licence Agreement in Lung Cancer
    Cancer Research UK, Cancer Research Technology (CRT), the charity’s commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
  • 23 September 2016
    Academician Sang Guowei Visits HitGen LTD
    September 22, 2016, Chengdu – Academician Sang Guowei, the Vice Chairperson of the National People’s Congress of the Peoples’ Republic of China, Chief Engineer of National Major Innovative Drug Projects as well as an Academician of the Chinese Academy of Engineering, accompanied by officials from Sichuan Provincial and Chengdu Municipal Government visited HitGen Ltd. Dr. Jin Li, Chairman & CEO of HitGen, as well as department leaders showed our warm reception and hospitality to Professor Sang Guowei.
  • 22 September 2016
    HitGen Ltd. Collaborates with Johnson & Johnson
    Chengdu, China, September 22, 2016, HitGen Ltd., a privately held biotech company focused on technology for effective and efficient molecular discovery, announced today a multi-target global collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which has been facilitated by Johnson & Johnson Innovation. This collaboration is to discover potential new therapies in areas of strategic interest to Janssen, especially in the areas of oncology and metabolics.
  • 23 August 2016
    New Drug Discovery: Find Needles in Very Large Haystacks
    Aug 23th, as the first speaker of 5th IAPC Meeting, Dr. Jin Li introduced the technical principle of DNA Encoded Library (DELs) synthesis and screening and its potential impact on the early new drug discovery, which attracted several attendees’ interest.
  • 07 May 2016
    Nature Biotechnology: DNA-encoded Drug Libraries Come of Age
    May 6, 2016 – Nature Biotechnology published an article named “DNA-encoded Drug Libraries Come of Age”. In this article, it introduced the basic principles of DNA-encoded Libraries (DEL) and some major developments in innovative drug discoveries. It also gave recognition of contribution in innovative drug discoveries area made by those DEL companies at home and abroad including HitGen.
  • 30 April 2016
    Professor Richard A. Lerner and Professor K. Barry Sharpless Visit HitGen
    April 29, 2016, Chengdu – HitGen had the honor to host Professor Richard A. Lerner, former President of The Scripps Research Institute and Professor K. Barry Sharpless (winner of the 2001 Nobel Prize in Chemistry for catalyzed oxidation reactions) visit our site in Chengdu. Dr. Jin Li, Chairman & CEO of HitGen, as well as department leaders showed our warm reception and hospitality to the guests. Later on, both sides held a deeper and comprehensive discussion based on companies’ technologies, development, etc.
  • 26 April 2016
    Premier Li Keqiang Speaks Highly of HitGen’s Giant “Innovative Drug
    April 24, 2016 – HitGen, as a “high-tech pioneer” of biotechnology field in Sichuan Province, was inspected and encouraged by Premier Li Keqiang. The premier gave HitGen recognition on its rapid growth for the past 4 years and instructed HitGen urgently to translate the existing giant “Innovative Drug Discovery Library” to real innovative drugs that patients can use.
  • 31 January 2016
    HitGen Enters Into Research Collaboration with GBT
    Chengdu, China January 8, 2016 – HitGen LtD, a privately held drug discovery company that enables the extraordinary power of DNA encoded libraries with a patented proprietary platform to discover new therapeutic starting points, announced today a research collaboration with Global Blood Therapeutics, Inc. (NASDAQ: GBT), a clinical-stage biopharmaceutical company dedicated to novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs. HitGen will provide biology, chemistry, and screening to support GBT’s efforts around an undisclosed novel target.
  • 04 June 2015
    Drug Discovery Deal Signed between HitGen and Tasly
    Recently, Tasly Holding Group (Tasly, a major pharmaceutical company in China) held “Industry- Research-Investment Collaboration Signing Ceremony for its Big Health Project” in TianJin, China. In the event, Tasly signed 11 new drug discovery collaboration agreements with HitGen Ltd.(HitGen) and other 8 companies, research institutions. According to the agreement, HitGen will use its proprietary DNA Encoded Libraries to collaborate with Tasly. The collaboration has significant financial value.
  • 17 April 2015
    HitGen Announces Collaboration in Drug Discovery with Cyclofluidic Ltd
    Chengdu, China, 17 April 2015– HitGen Ltd today announced that it has entered into research collaboration with Cyclofluidic Ltd, UK, using hits obtained from HitGen’s proprietary lead discovery technology. Within the framework of the collaboration, novel allosteric inhibitors of GSK3b, a kinase implicated in neurodegenerative diseases, will be optimised using CyclOpsTM technology to provide advanced leads suitable for clinical development.

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information